Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NYSE:ATNM NASDAQ:ESLA NASDAQ:ME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$2.02-6.9%$1.84$1.21▼$3.81$49.89M0.68261,100 shs46,042 shsATNMActinium Pharmaceuticals$1.49-0.7%$1.63$1.03▼$2.41$46.48M-0.25364,399 shs136,548 shsESLAEstrella Immunopharma$1.29+4.9%$1.06$0.63▼$1.78$45.59M0.39139,558 shs92,892 shsME23andMe$0.50-35.3%$0.50$0.53▼$9.57$13.36M1.191.57 million shs29.28 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience+1.88%+11.86%+20.56%+13.61%+9.05%ATNMActinium Pharmaceuticals-0.67%-5.70%-7.45%-1.97%-4.79%ESLAEstrella Immunopharma+4.88%-1.53%+21.70%+46.61%+42.94%ME23andMe0.00%0.00%0.00%0.00%-91.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$2.02-6.9%$1.84$1.21▼$3.81$49.89M0.68261,100 shs46,042 shsATNMActinium Pharmaceuticals$1.49-0.7%$1.63$1.03▼$2.41$46.48M-0.25364,399 shs136,548 shsESLAEstrella Immunopharma$1.29+4.9%$1.06$0.63▼$1.78$45.59M0.39139,558 shs92,892 shsME23andMe$0.50-35.3%$0.50$0.53▼$9.57$13.36M1.191.57 million shs29.28 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience+1.88%+11.86%+20.56%+13.61%+9.05%ATNMActinium Pharmaceuticals-0.67%-5.70%-7.45%-1.97%-4.79%ESLAEstrella Immunopharma+4.88%-1.53%+21.70%+46.61%+42.94%ME23andMe0.00%0.00%0.00%0.00%-91.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/AATNMActinium Pharmaceuticals 3.00Buy$4.50202.01% UpsideESLAEstrella Immunopharma 2.00Hold$16.001,140.31% UpsideME23andMe 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ME, ATNM, ESLA, and AADI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ESLAEstrella ImmunopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ESLAEstrella ImmunopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/12/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.99N/AN/A$4.29 per share0.47ATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%11/4/2025 (Estimated)ATNMActinium Pharmaceuticals-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/AESLAEstrella ImmunopharmaN/A-$0.26N/A∞N/AN/A-1,132.38%-358.54%11/13/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54ATNMActinium PharmaceuticalsN/A10.2510.25ESLAEstrella ImmunopharmaN/A0.160.16ME23andMeN/A1.050.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%ATNMActinium Pharmaceuticals27.50%ESLAEstrella Immunopharma0.35%ME23andMe36.10%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%ATNMActinium Pharmaceuticals6.00%ESLAEstrella Immunopharma55.10%ME23andMe26.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableESLAEstrella ImmunopharmaN/A37.07 million16.64 millionNot OptionableME23andMe77026.83 million19.77 millionNot OptionableME, ATNM, ESLA, and AADI HeadlinesRecent News About These CompaniesDNA Privacy Is Falling Apart and 23andMe Is at the Center2 hours ago | msn.comAncestryDNA or 23andMe? How to choose the best DNA kitOctober 10 at 7:46 PM | businessinsider.comCredential stuffing: £2.31 million fine shows passwords are still the weakest linkOctober 7, 2025 | theregister.comTHere's how much the 23andMe data breach settlement could pay youOctober 3, 2025 | bizjournals.com23andMe Files Second Amended Bankruptcy PlanOctober 1, 2025 | tipranks.com23andMe Nets Approval of Data Breach Settlements in BankruptcySeptember 26, 2025 | news.bloomberglaw.comN23andMe Bankruptcy Judge to Rule Soon on Data Breach SettlementsSeptember 25, 2025 | news.bloomberglaw.comNWhat Causes Stuttering? A Large DNA Analysis Study Offers New Clues, Uncovering Links to 48 GenesSeptember 25, 2025 | smithsonianmag.comS23andMe Holding Files for Chapter 11 BankruptcySeptember 22, 2025 | tipranks.comLA firm backs St. Louis-based VeloSource, fueling expansion of medical staffing servicesSeptember 17, 2025 | bizjournals.comBambu Ventures Set to Acquire Telemedicine Pioneer Lemonaid Health Through SPV Amid Chrome Holding Co.'s Bankruptcy ProceedingsSeptember 16, 2025 | hoodline.comH23andMe Bankruptcy Plan Prompts Objection From 30,000 ClaimantsSeptember 15, 2025 | news.bloomberglaw.comN23andMe Offers $3.25 Million Deal for Canadian Data Breach ClassSeptember 12, 2025 | news.bloomberglaw.comN23andMe Seeks Court Approval of $50 Million Data Breach DealSeptember 6, 2025 | news.bloomberglaw.comNThese scientists found Alzheimer's in their genes. Here's what they did nextSeptember 3, 2025 | npr.orgNWhat causes stuttering? It might be in your DNASeptember 3, 2025 | npr.orgNThese scientists found Alzheimer’s in their genes. Here’s what they did nextSeptember 2, 2025 | thepublicsradio.orgTJaylen Brown: "I did my history — my 23andMe. TheyAugust 25, 2025 | msn.comWayne State study says stuttering isn’t your nerves, it’s your genesAugust 24, 2025 | 953mnc.com923andMe Board Approves Changes to CEO’s CompensationAugust 22, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Downgraded But Not Done: 3 Stocks Ready for a Market ComebackBy Thomas Hughes | September 24, 2025Carmax: Now is the Time to Load Up On This Used Car StockBy Thomas Hughes | September 26, 20253 Quantum Computing ETFs to Know—And Why 2 Don't Hold D-WaveBy Nathan Reiff | September 23, 2025ME, ATNM, ESLA, and AADI Company DescriptionsAadi Bioscience NASDAQ:AADI$2.02 -0.15 (-6.91%) As of 10/10/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Actinium Pharmaceuticals NYSE:ATNM$1.49 -0.01 (-0.67%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.45 -0.04 (-2.68%) As of 10/10/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Estrella Immunopharma NASDAQ:ESLA$1.29 +0.06 (+4.88%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$1.30 +0.01 (+1.16%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.23andMe NASDAQ:ME23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
